The ten best articles in the medical literature relating to ovarian and other gyneologic cancers are reviewed here.
Adjuvant pelvic radiotherapy following radical surgery reduces the number of recurrences in women with stage IB cervical cancer at the cost of 6% grade 3/4 adverse events vs 2.1% in the group with no further therapy. Regimens of radiotherapy and chemotherapy that contain cisplatin improve the rates of survival and progression-free survival among women with locally advanced cervical cancer.
Orr JW Jr, Holimon JL, Orr PF. Stage I corpus cancer: is teletherapy necessary? Am J Obstet Gynecol. 1997; 176:777-789. Extensive surgical staging including lymphadenectomy can be performed safely. The authors suggest that the risk of pelvic recurrence is not increased, and the risk of survival is not compromised in those women not receiving adjunctive teletherapy.
Trimble EL, Kosary C, Park RC. Lymph node sampling and survival in endometrial cancer. Gynecol Oncol. 1998; 71:340-343. In their review of SEER data on women with stage I-II endometrial cancer, lymph node sampling was associated with increased survival among patients with stage I, grade 3 disease but not grade 1 or 2. The observed survival benefit may be due to identification of women with more advanced endometrial cancer. Accurate determination of grade and extent of tumor is necessary to delineate which patients may benefit from lymph node sampling at hysterectomy. Among the conclusions from a recent consensus committee was that in previously untreated advanced ovarian cancer, cisplatin plus paclitaxel has been shown to be superior to previous standard therapy with cisplatin plus cyclophosphamide. However, for many patients, carboplatin plus paclitaxel is a reasonable alternative because of toxicity and convenience issues. The benefits in terms of toxicity for the paclitaxel-carboplatin combination indicate that its widespread adoption at this stage is justified. Sessa C, ten Bokkel Huinink WW, du Bois A. Oxaliplatin in ovarian cancer. Ann Oncol. 1999;10 (Suppl 1):55-57.
The antitumor activity so far observed in phase II studies in which oxaliplatin was given for ovarian cancer ranged between 15% and 30% and has confirmed the preclinical data. These results support the need for additional studies in patients with tumor primarily resistant to cisplatin to establish a role of oxaliplatin in ovarian cancer. Neurotoxicity is the most important side effect.
Frank TS, Manley SA, Olopade OI, et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998; 16:2417 -2425 Because mutations in BRCA1 and BRCA2 in women with breast cancer are associated with an increased risk of ovarian cancer, analysis of these genes should be considered for women diagnosed with breast cancer who have a high probability of carrying a mutation according to the statistical model developed with these data.
Greten TF, Jaffee EM. Cancer vaccines. J Clin Oncol. 1999;17: 1047-1060.
Improved molecular biology techniques and a greater understanding of the mechanisms involved in the activation of T cells have allowed the design of more specific cancer vaccine approaches. These advances have resulted in improved systemic antitumor immune responses in animal models.
